研究活動・実績

  1. Home
  2. 研究活動・実績
  3. 論文業績

論文業績

Paper

乳腺・内分泌外科学講座
過去の原著論文および総説

乳癌は嘗て日本では罹患率の低い癌であったが、生活習慣の欧米化に伴いその罹患率は急増している。現在では女性で最も罹患率の高い癌となり、年間の新規罹患者数は約5万人、乳癌死亡者数は約1.2万人である。乳癌の治療成績の更なる向上のためには個別化治療の実施が必須と考えられるが、そのために個々の乳癌の生物学的特性を正確に診断し得る高精度の分子診断法の開発が不可欠である。当教室では、従来の病理診断では診断し得なかった乳癌の特性を診断し得る新しい分子診断法の開発に取り組んでいる。また、多施設共同の臨床試験（ホルモン療法、化学療法、分子標的治療等）にも主導的な立場で積極的に参画している。以下に現在までの業績を記載する。

原著論文

 
1. Zardavas D, Te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, Razis E, Papaxoinis G, Joensuu H, Moynahan ME, Hennessy BT, Bieche I, Saal LH, Stal O, Iacopetta B, Jensen JD, O'Toole S, Lopez-Knowles E, Barbaraeschi M, Noguchi S, Azim HA, Jr., Lerma E, Bachelot T, Wang Q, Perez-Tenorio G, Can de Velde CJH, Rea DW, Sabine V, Bartlett JMS, Sotiriou C, Michiels S, Loi S. Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. J Clin Oncol 2018; 36: 981-990.
2. Robertson JFR, Cheung KL, Noguchi S, Shao Z, Degboe A, Lichfield J, Thirlwell J, Fazal M, Ellis MJ. Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer. Eur J Cancer 2018; 94: 206-215.
3. Ohashi Y, Shiba E, Yamashita H, Kurebayashi J, Noguchi S, Iwase H, Yoshida M, Fujimoto T. Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial. Support Care Cancer 2018; 26: 933-945.
4. Noguchi S, Ellis MJ, Robertson JFR, Thirlwell J, Fazal M, Shao Z. Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON). Breast Cancer 2018.
5. Nakayama T, Sagara Y, Takashima T, Matsunami N, Masuda N, Miyoshi Y, Taguchi T, Aono T, Ito T, Kagimura T, Noguchi S. Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC). Cancer Chemother Pharmacol 2018; 81: 755-762.
6. Mishima C, Kagara N, Ikeda JI, Morii E, Miyake T, Tanei T, Naoi Y, Shimoda M, Shimazu K, Kim SJ, Noguchi S. Mutational Analysis of AKT1 and PIK3CA in Intraductal Papillomas of the Breast with Special Reference to Cellular Components. Am J Pathol 2018.
7. Matsui S, Kagara N, Mishima C, Naoi Y, Shimoda M, Shimomura A, Shimazu K, Kim SJ, Noguchi S. LATS2 promoter hypermethylation and its effect on gene expression in human breast cancer. Oncol Lett 2018; 15: 2595-2603.
8. Masunaga N, Kagara N, Motooka D, Nakamura S, Miyake T, Tanei T, Naoi Y, Shimoda M, Shimazu K, Kim SJ, Noguchi S. Highly sensitive detection of ESR1 mutations in cell-free DNA from patients with metastatic breast cancer using molecular barcode sequencing. Breast Cancer Res Treat 2018; 167: 49-58.
 
1. Yanagawa T, Kagara N, Miyake T, Tanei T, Naoi Y, Shimoda M, Shimazu K, Kim SJ, Noguchi S. Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing. Breast Cancer Res Treat 2017; 163: 231-240.
2. Robertson JFR, Cheung KL, Noguchi S, Shao Z, Degboe A, Lichfield J, Thirlwell J, Fazal M, Ellis MJ. Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer. Eur J Cancer 2018; 94: 206-215.
3. Ohashi Y, Shiba E, Yamashita H, Kurebayashi J, Noguchi S, Iwase H, Yoshida M, Fujimoto T. Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial. Support Care Cancer 2018; 26: 933-945.
4. Noguchi S, Ellis MJ, Robertson JFR, Thirlwell J, Fazal M, Shao Z. Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON). Breast Cancer 2018.
5. Nakayama T, Sagara Y, Takashima T, Matsunami N, Masuda N, Miyoshi Y, Taguchi T, Aono T, Ito T, Kagimura T, Noguchi S. Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC). Cancer Chemother Pharmacol 2018; 81: 755-762.
6. Mishima C, Kagara N, Ikeda JI, Morii E, Miyake T, Tanei T, Naoi Y, Shimoda M, Shimazu K, Kim SJ, Noguchi S. Mutational Analysis of AKT1 and PIK3CA in Intraductal Papillomas of the Breast with Special Reference to Cellular Components. Am J Pathol 2018.
7. Matsui S, Kagara N, Mishima C, Naoi Y, Shimoda M, Shimomura A, Shimazu K, Kim SJ, Noguchi S. LATS2 promoter hypermethylation and its effect on gene expression in human breast cancer. Oncol Lett 2018; 15: 2595-2603.
8. Masunaga N, Kagara N, Motooka D, Nakamura S, Miyake T, Tanei T, Naoi Y, Shimoda M, Shimazu K, Kim SJ, Noguchi S. Highly sensitive detection of ESR1 mutations in cell-free DNA from patients with metastatic breast cancer using molecular barcode sequencing. Breast Cancer Res Treat 2018; 167: 49-58.
9 Yanagawa T, Kagara N, Miyake T, Tanei T, Naoi Y, Shimoda M, Shimazu K, Kim SJ, Noguchi S. Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing. Breast Cancer Res Treat 2017; 163: 231-240.
 
1. Noguchi S. Japanese contribution to the field of sentinel lymph node biopsy for breast cancer patients: introduction to invited articles. Int J Clin Oncol 2017; 22: 1-2
2. Naoi Y, Noguchi S. Multi-gene classifiers for prediction of recurrence in breast cancer patients. Breast Cancer 2016; 23: 12-18.
3. Shimazu K, Noguchi S. Clinical significance of breast cancer micrometastasis in the sentinel lymph node. Surg Today 2015.
4. Shimazu K, Noguchi S. Sentinel lymph node biopsy before versus after neoadjuvant chemotherapy for breast cancer. Surg Today 2011; 41: 311-316.
5. Nakayama T, Noguchi S. Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan. Oncologist 2010; 15: 26-36.
6. Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kono S, Morimoto K, Kim SJ, Okishiro M, Yanagisawa T, Ueda S, Taguchi T, Tamaki Y, Noguchi S. Predictive factors for anthracycline-based chemotherapy for human breast cancer. Breast Cancer 2010; 17: 103-109.
7. Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kono S, Morimoto K, Kim SJ, Okishiro M, Yanagisawa T, Ueda S, Taguchi T, Tamaki Y, Noguchi S. Predictive factors for anthracycline-based chemotherapy for human breast cancer. Breast Cancer 2010; 17: 103-109.
8. Chlebowski R, Cuzick J, Amakye D, Bauerfeind I, Buzdar A, Chia S, Cutuli B, Linforth R, Maass N, Noguchi S, Robidoux A, Verma S, Hadji P. Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast 2009; 18 Suppl 2: S1-11.
9 Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006; 97: 813-820.
10 Tamaki Y, Miyoshi Y, Kim SJ, Tanji Y, Taguchi T, Noguchi S. Aromatase inhibitors for treatment of postmenopausal patients with breast cancer. Expert Rev Anticancer Ther 2003; 3: 193-201.
11 Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S. Current status of endocrine therapy for breast cancer. Breast Cancer 2003; 10: 105-111.
12 Miyoshi Y, Noguchi S. Polymorphisms of estrogen synthesizing and metabolizing genes and breast cancer risk in Japanese women. Biomed Pharmacother 2003; 57: 471-481.
13 Tamaki Y, Tsukamoto F, Miyoshi Y, Tanji Y, Taguchi T, Noguchi S. Overview: video-assisted breast surgery. Biomed Pharmacother 2002; 56 Suppl 1: 187s-191s.
14 Tamaki Y, Miyoshi Y, Noguchi S. Adjuvant hormonal therapy. Breast Cancer 2002; 9: 185-189./td>
15 Motomura K, Inaji H, Komoike Y, Kasugai T, Nagumo S, Noguchi S, Koyama H. Sentinel Node Biopsy in Breast Cancer. Breast Cancer 1999; 6: 289-291.
16 Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H, Kasugai T, Wada A. Phyllodes Tumor of the Breast: Pathology, Histogenesis, Diagnosis, and Treatment. Breast Cancer 1996; 3: 79-92.
17 Koyama H, Inaji H, Noguchi S, Motomura K. Recent Progress in Breast Conserving Therapy: From Experiences in Japan. Breast Cancer 1996; 3: 151-160.